Five-Year Antibody Persistence Following a Japanese Encephalitis Chimeric Virus Vaccine (JE-CV) Booster in JE-CV-Primed Children in the Philippines

Maria Rosario Capeding, Edison R Alberto, Alain Bouckenooghe, Thelma M Laot, Danaya Chansinghakul, Céline Monfredo, Tifany Machabert, Emmanuel Feroldi, Maria Rosario Capeding, Edison R Alberto, Alain Bouckenooghe, Thelma M Laot, Danaya Chansinghakul, Céline Monfredo, Tifany Machabert, Emmanuel Feroldi

Abstract

NCT01190228.

Keywords: IMOJEV; JE-CV; Japanese encephalitis; Philippines; live attenuated Japanese encephalitis vaccine.

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Disposition of participants. *Feroldi et al [5]. Abbreviations: D, day; GPO-MBP, Government Pharmaceutical Organization–Mérieux Biological Products; JE-CV, Japanese encephalitis chimeric virus vaccine; n, number of participants; US, United States.

References

    1. Lopez AL, Aldaba JG, Roque VG Jr et al. . Epidemiology of Japanese encephalitis in the Philippines: a systematic review. PLoS Negl Trop Dis 2015; 9:e0003630.
    1. Rappler. DOH warns vs mosquito bites after 9 deaths from Japanese encephalitis . Accessed 20 September 2017.
    1. Heffelfinger JD, Li X, Batmunkh N et al. . Japanese encephalitis surveillance and immunization—Asia and Western Pacific Regions, 2016. Morb Mortal Wkly Rep 2017; 66:579–83.
    1. Wang H, Liang G. Epidemiology of Japanese encephalitis: past, present, and future prospects. Ther Clin Risk Manag 2015; 11:435–48.
    1. Feroldi E, Capeding MR, Boaz M, Gailhardou S, Meric C, Bouckenooghe A. Memory immune response and safety of a booster dose of Japanese encephalitis chimeric virus vaccine (JE-CV) in JE-CV-primed children. Hum Vaccin Immunother 2013; 9:889–97.
    1. Kosalaraksa P, Watanaveeradej V, Pancharoen C, Capeding MR, Feroldi E, Bouckenooghe A. Long-term immunogenicity of a single dose of Japanese encephalitis chimeric virus vaccine in toddlers and booster response 5 years after primary immunization. Pediatr Infect Dis J 2017; 36:e108–13.
    1. Feroldi E, Pancharoen C, Kosalaraksa P et al. . Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12-18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother 2012; 8:929–37.
    1. Chambers TJ, Nestorowicz A, Mason PW, Rice CM. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J Virol 1999; 73:3095–101.
    1. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2–3 September, 2004. Vaccine 2005; 23:5205–11.
    1. So Y, Johnston G, Kim SE.. Analyzing interval-censored survival data with SAS software, paper 257–2010. SAS Global Forum 2010. . Accessed 12 December 2017.
    1. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U et al. . Long-term follow-up of Japanese encephalitis chimeric virus vaccine: immune responses in children. Vaccine 2016; 34:5664–9.
    1. Janewongwirot P, Puthanakit T, Anugulruengkitt S et al. . Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children. Vaccine 2016; 34:5279–83.
    1. Chokephaibulkit K, Sirivichayakul C, Thisyakorn U et al. . Safety and immunogenicity of a single administration of live-attenuated Japanese encephalitis vaccine in previously primed 2- to 5-year-olds and naive 12- to 24-month-olds: multicenter randomized controlled trial. Pediatr Infect Dis J 2010; 29:1111–7.
    1. Pan XL, Liu H, Wang HY et al. . Emergence of genotype I of Japanese encephalitis virus as the dominant genotype in Asia. J Virol 2011; 85:9847–53.
    1. Feroldi E, Boaz M, Yoksan S et al. . Persistence of wild-type Japanese encephalitis virus strains cross-neutralization 5 years after JE-CV immunization. J Infect Dis 2017; 215:221–7.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe